- Home
- PFN vs LXRX Comparison
PFN vs LXRX Comparison
Compare PFN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFN
- LXRX
- Stock Information
- Founded
- PFN 2004
- LXRX 1995
- Country
- PFN United States
- LXRX United States
- Employees
- PFN N/A
- LXRX N/A
- Industry
- PFN Finance/Investors Services
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- PFN Finance
- LXRX Health Care
- Exchange
- PFN Nasdaq
- LXRX Nasdaq
- Market Cap
- PFN 625.5M
- LXRX 690.5M
- IPO Year
- PFN N/A
- LXRX 2000
- Fundamental
- Price
- PFN $7.40
- LXRX $1.61
- Analyst Decision
- PFN
- LXRX Buy
- Analyst Count
- PFN 0
- LXRX 2
- Target Price
- PFN N/A
- LXRX $10.00
- AVG Volume (30 Days)
- PFN 331.7K
- LXRX 2.6M
- Earning Date
- PFN 01-01-0001
- LXRX 08-01-2024
- Dividend Yield
- PFN 11.66%
- LXRX N/A
- EPS Growth
- PFN N/A
- LXRX N/A
- EPS
- PFN N/A
- LXRX N/A
- Revenue
- PFN N/A
- LXRX $3,641,000.00
- Revenue This Year
- PFN N/A
- LXRX $1,288.95
- Revenue Next Year
- PFN N/A
- LXRX $276.56
- P/E Ratio
- PFN N/A
- LXRX N/A
- Revenue Growth
- PFN N/A
- LXRX 794.59
- 52 Week Low
- PFN $5.94
- LXRX $0.92
- 52 Week High
- PFN $7.58
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- PFN 65.40
- LXRX 41.99
- Support Level
- PFN $7.30
- LXRX $1.66
- Resistance Level
- PFN $7.39
- LXRX $1.87
- Average True Range (ATR)
- PFN 0.05
- LXRX 0.12
- MACD
- PFN 0.01
- LXRX -0.01
- Stochastic Oscillator
- PFN 82.76
- LXRX 11.63
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.